clinical trial · NCT06924710
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
Peking University Cancer Hospital & Institute·N/A·recruiting·n = 286
NSCLCStandard TherapyAdaptive Therapy
brief summary
It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.
started
Apr 6, 2025
primary completion
Jun 15, 2029
completion
Dec 31, 2029
last updated
Oct 2, 2025
official title
A Prospective Multicenter Randomized Controlled Study of Adaptive Therapy in Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol